drugset / Trial / NCT04166669
A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1, open-label study to evaluate the drug-drug interaction potential of a strong CYP3A4 inhibitor (itraconazole) and a pan-CYP inducer (rifampin) on APX001 in two parallel groups of healthy subjects.
Timeline
- Start
- 2019-11-12
- Primary completion
- 2020-03-03
- Completion
- 2020-03-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fosmanogepix | Small molecule | 500 mg | Intravenous |
| Subject | Fosmanogepix | Small molecule | 1000 mg | Intravenous |
| Subject | Itraconazole | Small molecule | 200 mg | Oral |
| Subject | Rifampin | Small molecule | 600 mg | Oral |